Top-News

CAC 40 Index

Index
WKN:  969400 ISIN:  FR0003500008
8.124,05
-0,19%
-15,167
16.12.25
Depot/Watchlist
Weiter abwärts? Short handeln - Jetzt mit Hebel 22,52: MG49LP
Werbung

Ad-hocs

24.09.25 - GlobeNewswire
L'Oréal Executive Committee Nominations
INCLUDING NEW ROLES FOR DAVID GREENBERG, ALEXIS PERAKIS-​VALAT, FABRICE MEGARBANE, VIANNEY DERVILLE AND EMMANUEL GOULIN, WITH EVA YU JOINING THE ...
24.09.25 - GlobeNewswire
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24.09.25 - GlobeNewswire
Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire
23.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-​congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, ...
22.09.25 - EQS
EQS-Adhoc: Airbus reports share buyback transactions 15-19 September 2025
EQS-​Ad-hoc: Airbus SE / Key word(s): Share Buyback Airbus reports share buyback transactions 15-19 September 2025 22-Sep-2025 / 17:45 CET/CEST Disclosure of an inside ...
22.09.25 - GlobeNewswire
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Update on the US regulatory review of tolebrutinib in non-​relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration ...
22.09.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 ...
17.09.25 - GlobeNewswire
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary ...
15.09.25 - EQS
EQS-Adhoc: Airbus reports share buyback transactions 8-12 September 2025
EQS-​Ad-hoc: Airbus SE / Key word(s): Share Buyback Airbus reports share buyback transactions 8-12 September 2025 15-Sep-2025 / 17:45 CET/CEST Disclosure of an inside ...
11.09.25 - GlobeNewswire
Capgemini launches its twelfth Employee Share Ownership Plan
Media relations: Victoire Grux Tel.: +33 6 04 52 16 55 victoire.grux@capgemini.com
11.09.25 - GlobeNewswire
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-​related macular degeneration Designation earned for a one-time intravitreal gene therapy with the ...
10.09.25 - GlobeNewswire
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Tzield approved in China as first disease-​modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
08.09.25 - EQS
EQS-Adhoc: Airbus SE: Airbus commences limited share buyback to support future employee share ownership plan activities and equity-based compensation
EQS-​Ad-hoc: Airbus SE / Key word(s): Miscellaneous Airbus SE: Airbus commences limited share buyback to support future employee share ownership plan activities and equity-...
04.09.25 - GlobeNewswire
Disclosure of total number of voting rights and number of shares in the capital at August 31, 2025
French limited company (Société anonyme) with registered capital of 106,640,982.60 e uros Registered office: 14, rue Royale, 75008 Paris 632 012 100 R.C.S. Paris Legal Entity ...
29.08.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-​immune modulation to help address root causes of ...
26.08.25 - GlobeNewswire
Capgemini to acquire Cloud4C, a leader in hybrid cloud platform services
Media relations: Sam Connatty Tel.: +44 370 904 3601 Email: sam.connatty@capgemini.com
14.08.25 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related ...
06.08.25 - GlobeNewswire
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc.
05.08.25 - GlobeNewswire
LVMH: Share transactions disclosure
Paris, August 5 th , 2025
04.08.25 - GlobeNewswire
Disclosure of total number of voting rights and number of shares in the capital at July 31, 2025
French limited company (Société anonyme) with registered capital of 106,640,982.60 euros Registered office: 14, rue Royale, 75008 Paris 632 012 100 R.C.S. Paris Legal Entity ...

Newssuche

Videos

newspaper
16.12.25 -3,03%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »